Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 4:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: CHRONIC DISEASE Clear all
Completed Phase 1 Interventional

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

NCT00054236
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, filgrastim, cyclophosphamide, fludarabine phosphate, umbilical cord blood transplantation, methylprednisolone
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Sep 12, 2026, 4:35 AM EDT
Terminated Not applicable Interventional Results available

Integrating Conservative Kidney Management Options and Advance Care Planning Into a Pre-Dialysis Educational Program

NCT03229811
View directory record Official record
Conditions
Advance Care Planning, Chronic Kidney Diseases, Conservative Kidney Management
Interventions
ESRD education + conservative kidney management and ACP education
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Sep 12, 2026, 4:35 AM EDT
Terminated Phase 3 Interventional Results available

Simvastatin Therapy for Moderate and Severe COPD

NCT01061671
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
simvastatin, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 80 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2018 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Phase 4 Interventional

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

NCT01742299
View directory record Official record
Conditions
GIST and CML
Interventions
imatinib mesylate
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Years to 100 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Phase 2 Interventional

Dose-Ranging Study of A006 DPI, in Adult Asthma Patients

NCT01174732
View directory record Official record
Conditions
Asthma, Bronchospasm
Interventions
albuterol inhalation powder, Placebo, albuterol inhalation aerosol
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
San Jose, California • Centennial, Colorado • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Sep 12, 2026, 4:35 AM EDT
Completed No phase listed Observational

Insulin Dosing in Diabetic Patients With End Stage Renal Disease (ESRD) or Hemodialysis

NCT02083133
View directory record Official record
Conditions
Diabetes, Hypoglycemia, Renal Dysfunction, Insulin Dosing
Interventions
Not listed
Lead sponsor
Cook County Health
Government
Eligibility
18 Years to 99 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Phase 4 Interventional

Paroxetine in the Treatment of Chronic Primary Insomnia

NCT00178048
View directory record Official record
Conditions
Primary Insomnia, Depression
Interventions
paroxetine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
55 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 14, 2005 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Phase 1 Interventional

Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

NCT00345826
View directory record Official record
Conditions
Leukemia
Interventions
dasatinib
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury

NCT00041717
View directory record Official record
Conditions
Spinal Cord Injury, Muscle Spasticity
Interventions
Fampridine-SR, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 12, 2026, 4:35 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)

NCT06852768
View directory record Official record
Conditions
oGHVD
Interventions
d-MAPPS, Placebo, PI and Patient Masked
Biological · Other
Lead sponsor
Regenerative Ocular Immunobiologics LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Beverly Hills, California • Huntington Beach, California • Palm Harbor, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

NCT00235391
View directory record Official record
Conditions
Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Myelofibrosis
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
1,683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
27
States / cities
Little Rock, Arkansas • Berkeley, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Not applicable Interventional Results available

Reducing Cannabis Use for Sleep Among Adults Using Medical Cannabis

NCT03964974
View directory record Official record
Conditions
Insomnia Chronic, Cannabis Use
Interventions
Cognitive Behavioral Therapy for Insomnia in Cannabis Users (CBTi-CB), Sleep Hygiene Education (SHE)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Phase 1 Interventional

Lithium Long COVID Dose-finding Study

NCT06108297
View directory record Official record
Conditions
Long COVID
Interventions
Lithium
Dietary Supplement
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Phase 1 Interventional

Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis

NCT00003368
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
45
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

NCT02281084
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Oral Azacitidine, Durvalumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
23
States / cities
New Haven, Connecticut • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Sep 12, 2026, 4:35 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Supporting Resilience Among Re-entered Seniors

NCT06276452
View directory record Official record
Conditions
Chronic Disease
Interventions
Psychoeducation
Behavioral
Lead sponsor
University of Louisville
Other
Eligibility
45 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 12, 2026, 4:35 AM EDT
Not yet recruiting Phase 1 Interventional

Anti-Interleukin-6 (IL6) in Calciphylaxis

NCT07708038
View directory record Official record
Conditions
Calciphylaxis
Interventions
Tocilizumab
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 12, 2026, 4:35 AM EDT
Active, not recruiting Not applicable Interventional

HOBSCOTCH for People With Post Acute COVID-19 Syndrome (PACS)

NCT06391489
View directory record Official record
Conditions
Post Acute COVID 19 Syndrome, Memory Impairment, Memory Dysfunction, Cognitive Dysfunction
Interventions
HOBSCOTCH-PACS
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
20 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 12, 2026, 4:35 AM EDT
Terminated Phase 2 Interventional

Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide

NCT00041574
View directory record Official record
Conditions
Pulmonary Hypertension, Lung Disease, Sickle Cell Disease, Cardiac Transplant, Lung Transplant
Interventions
Inhaled Nitric Oxide
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
5 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
3
States / cities
Denver, Colorado • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Not applicable Interventional

Exercise Training to Promote Resilience to Chronic Lymphocytic Leukemia

NCT04950452
View directory record Official record
Conditions
Aging, Chronic Lymphocytic Leukemia
Interventions
Exercise Training
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Sep 12, 2026, 4:35 AM EDT
Completed No phase listed Observational

Kinetic Biomarker for Chronic Lymphocytic Leukemia Prognosis

NCT00481858
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Not listed
Lead sponsor
KineMed
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
5
States / cities
San Diego, California • Rochester, Minnesota • New Hyde Park, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2011 · Synced Sep 12, 2026, 4:35 AM EDT
Recruiting Phase 2 Interventional

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

NCT01962415
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
Interventions
Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks

NCT01555125
View directory record Official record
Conditions
Moderate to Severe Plaque-type Psoriasis
Interventions
secukinumab 150 mg, secukinumab 300 mg, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
18
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Phase 1 Interventional

Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation

NCT01634217
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
Interventions
iTreg
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Sep 12, 2026, 4:35 AM EDT